Physician profile
Nisha Soneji
NPI 1366006207
$2,316.23
in general payments reported to CMS, 2019-2025
14 companies · $358 in 2025
The $358 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $441 · 2023: $822 · 2024: $695 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,637 · Education: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,636.91 |
| Education | $238.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $576.16 | 2023-2025 | Ensite, Thoratec Heartmate 3 Lvas Implant Kit, Optis |
| Amgen INC. | $411.49 | 2024-2025 | Repatha |
| Abiomed | $253.82 | 2022-2023 | Impella |
| Boston Scientific Corporation | $233.77 | 2023-2024 | |
| Lantheus Medical Imaging, INC. | $180.75 | 2022-2023 | Definity |
| E.R. Squibb & Sons, L.L.C. | $153.61 | 2024-2025 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $143.98 | 2022-2023 | Lifevest |
| Medtronic, INC. | $113.95 | 2025 | Symplicity G3 |
| Merck Sharp & Dohme LLC | $98.51 | 2023 | Verquvo |
| Edwards Lifesciences Corporation | $47.01 | 2025 | Sapien 3 Ultra Resilia |
| Impulse Dynamics (USA) INC. | $33.43 | 2023 | Optimizer |
| Pfizer INC. | $26.24 | 2025 | |
| Novartis Pharmaceuticals Corporation | $23.75 | 2022 | |
| Chiesi USA, INC. | $19.76 | 2024 | Kengreal, Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nisha Soneji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.